Michael R Law1, Lucy Cheng2, Heather Worthington2, Muhammad Mamdani2, Kimberlyn M McGrail2, Fiona K I Chan2, Sumit R Majumdar2. 1. Centre for Health Services and Policy Research (Law, Cheng, Worthington, McGrail, Chan), School of Population and Public Health, University of British Columbia, Vancouver, BC; Li Ka Shing Centre for Health-care Analytics Research and Training (Mamdani), St. Michael's Hospital, Toronto, Ont.; Department of Medicine (Majumdar), University of Alberta, Edmonton, Alta. michael.law@ubc.ca. 2. Centre for Health Services and Policy Research (Law, Cheng, Worthington, McGrail, Chan), School of Population and Public Health, University of British Columbia, Vancouver, BC; Li Ka Shing Centre for Health-care Analytics Research and Training (Mamdani), St. Michael's Hospital, Toronto, Ont.; Department of Medicine (Majumdar), University of Alberta, Edmonton, Alta.
Abstract
BACKGROUND: Income-based deductibles are present in several provincial public drug plans in Canada and have been the subject of extensive debate. We studied the impact of such deductibles in British Columbia's Fair PharmaCare plan on drug and health care utilization among older adults. METHODS: We used a quasi-experimental regression discontinuity design to compare the impact of deductibles in BC's PharmaCare plan between older community-dwelling adults registered for the plan who were born in 1928 through 1939 (no deductible) and those born in 1940 through 1951 (deductible equivalent to 2% of household income). We used 1.2 million person-years of data between 2003 and 2015 to study public drug plan expenditures, overall drug use, and physician and hospital resource utilization in these 2 groups. RESULTS: The income-based deductible led to a 28.6% decrease in person-years in which public drug plan benefits were received (95% confidence interval [CI] -29.7% to -27.5%) and to a reduction in the per capita extent of annual benefits by $205.59 (95% CI -$247.81 to -$163.37). Despite this difference in public subsidy, we found no difference in the number of drugs received or in total drug spending once privately paid amounts were accounted for (p = 0.4 and 0.8, respectively). Further, we found only small or nonexistent changes in health care resource utilization at the 1939 threshold. INTERPRETATION: A modest income-based deductible had a considerable impact on the extent of public subsidy for prescription drugs. However, it had only a trivial impact on overall access to medicines and use of other health services. Unlike copayments, modest income-based deductibles may safely reduce public spending on drugs for some population groups.
BACKGROUND: Income-based deductibles are present in several provincial public drug plans in Canada and have been the subject of extensive debate. We studied the impact of such deductibles in British Columbia's Fair PharmaCare plan on drug and health care utilization among older adults. METHODS: We used a quasi-experimental regression discontinuity design to compare the impact of deductibles in BC's PharmaCare plan between older community-dwelling adults registered for the plan who were born in 1928 through 1939 (no deductible) and those born in 1940 through 1951 (deductible equivalent to 2% of household income). We used 1.2 million person-years of data between 2003 and 2015 to study public drug plan expenditures, overall drug use, and physician and hospital resource utilization in these 2 groups. RESULTS: The income-based deductible led to a 28.6% decrease in person-years in which public drug plan benefits were received (95% confidence interval [CI] -29.7% to -27.5%) and to a reduction in the per capita extent of annual benefits by $205.59 (95% CI -$247.81 to -$163.37). Despite this difference in public subsidy, we found no difference in the number of drugs received or in total drug spending once privately paid amounts were accounted for (p = 0.4 and 0.8, respectively). Further, we found only small or nonexistent changes in health care resource utilization at the 1939 threshold. INTERPRETATION: A modest income-based deductible had a considerable impact on the extent of public subsidy for prescription drugs. However, it had only a trivial impact on overall access to medicines and use of other health services. Unlike copayments, modest income-based deductibles may safely reduce public spending on drugs for some population groups.
Authors: Deirdre Hennessy; Claudia Sanmartin; Paul Ronksley; Rob Weaver; Dave Campbell; Braden Manns; Marcello Tonelli; Brenda Hemmelgarn Journal: Health Rep Date: 2016-06-15 Impact factor: 4.796
Authors: Aaron S Kesselheim; Krista F Huybrechts; Niteesh K Choudhry; Lisa A Fulchino; Danielle L Isaman; Mary K Kowal; Troyen A Brennan Journal: Am J Public Health Date: 2015-02 Impact factor: 9.308
Authors: Colin R Dormuth; Malcolm Maclure; Robert J Glynn; Peter Neumann; Alan M Brookhart; Sebastian Schneeweiss Journal: Clin Ther Date: 2008 Impact factor: 3.393
Authors: Benjamin Enns; Jeong Eun Min; Dimitra Panagiotoglou; Julio S G Montaner; Bohdan Nosyk Journal: BMC Health Serv Res Date: 2019-09-03 Impact factor: 2.655
Authors: Christopher J Longo; Margaret I Fitch; Jonathan M Loree; Linda E Carlson; Donna Turner; Winson Y Cheung; Darin Gopaul; Janet Ellis; Jolie Ringash; Maria Mathews; Jim Wright; Christiaan Stevens; David D'Souza; Robin Urquhart; Tuhin Maity; Fanor Balderrama; Evette Haddad Journal: Support Care Cancer Date: 2021-01-05 Impact factor: 3.603